Related Experiment Videos
[The effect of antibody against vascular endothelial growth factor on tumor growth]
Objective:
Vascular endothelial growth factor (VEGF) is a very important factor in the process of angiogenesis, which is chosen as a target for experimental study of anticancer.
Methods:
Anti-VEGF antibody was obtained from immunized rabbits and purified with affinity column. Morever, it was identified as neutralized antibody by Mile's assay.
Results:
The anti-VEGF antibody was able to inhibit growth of S180 sarcoma in a dose-dependent manner, and the inhibition rate reached 41.0% with dose 200 micrograms per mouse per day. For human gastric cancer (MGC-803)-bearing nude mice, Anti-VEGF antibody inhibited tumor growth by 76.2%. When anti-VEGF antibody was combined with 131I-3H11, a murine monoclonal antibody conjugated with 131I for treatment, only one of five nude mice developed tumor and 84.0% more inhibition of tumor growth was obtained in comparison with treatment by 131I-3H11 only.
Conclusion:
The anti-VEGF antibody may be potentially useful for clinical treatment of cancer.
Insights
An anti-vascular endothelial growth factor (VEGF) antibody effectively inhibited tumor growth in preclinical models. This antibody shows potential for clinical cancer treatment, demonstrating significant efficacy alone and in combination therapy.
Area of Science:
- Oncology
- Immunology
- Biotechnology